68Ga-Pentixafor PET in Combination With MRI Improves the Differential Diagnosis of Glioblastoma and Primary Central Nervous System Lymphoma
Zhenying Chen, Huimin Liu, Apeng Yang, Jingwei Liao, Zanyi Wu, Junmin Chen, Weibing MiaoPurposes
This study aims to investigate the diagnostic performance of combining 68Ga-pentixafor PET with MRI to differentiate primary central nervous system lymphoma (PCNSL) from glioblastoma (GBM), particularly focusing on atypical lymphoma identification.
Patients and Methods
Seventy-one PCNSL and 53 GBM patients who underwent both 68Ga-pentixafor PET/CT and MRI were retrospectively included. We evaluated the quantitative imaging parameters and MRI features of positive lesions, identifying atypical PCNSL by hemorrhage, necrosis, or heterogeneous enhancement. Logistic regression identified key variables, and the ROC-AUC evaluated their diagnostic value. Immunohistochemistry for CXCR4 was performed.
Results
PCNSLs, including 23 atypical cases, showed higher SUVmax and TBR, and lower MTV, ADCmin, and relative ADCmin (rADCmin) than GBMs (all
Conclusions
68Ga-pentixafor PET in combination with MRI provides valuable diagnostic information in differentiating PCNSL from GBM, especially for atypical PCNSL.